scPharmaceuticals Inc (SCPH)
3.54
-0.28
(-7.45%)
USD |
NASDAQ |
May 22, 16:00
3.51
-0.03
(-0.85%)
After-Hours: 20:00
scPharmaceuticals Enterprise Value: 108.57M for May 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 22, 2024 | 108.57M |
| May 21, 2024 | 118.85M |
| May 20, 2024 | 126.60M |
| May 17, 2024 | 152.20M |
| May 16, 2024 | 154.90M |
| May 15, 2024 | 145.71M |
| May 14, 2024 | 143.18M |
| May 13, 2024 | 137.77M |
| May 10, 2024 | 142.46M |
| May 09, 2024 | 154.36M |
| May 08, 2024 | 150.03M |
| May 07, 2024 | 157.60M |
| May 06, 2024 | 151.48M |
| May 03, 2024 | 148.95M |
| May 02, 2024 | 148.95M |
| May 01, 2024 | 144.62M |
| April 30, 2024 | 142.10M |
| April 29, 2024 | 146.07M |
| April 26, 2024 | 142.82M |
| April 25, 2024 | 137.77M |
| April 24, 2024 | 143.18M |
| April 23, 2024 | 147.15M |
| April 22, 2024 | 145.71M |
| April 19, 2024 | 145.35M |
| April 18, 2024 | 143.54M |
| Date | Value |
|---|---|
| April 17, 2024 | 140.30M |
| April 16, 2024 | 149.31M |
| April 15, 2024 | 156.16M |
| April 12, 2024 | 158.69M |
| April 11, 2024 | 164.82M |
| April 10, 2024 | 153.28M |
| April 09, 2024 | 161.93M |
| April 08, 2024 | 158.69M |
| April 05, 2024 | 162.29M |
| April 04, 2024 | 166.26M |
| April 03, 2024 | 168.78M |
| April 02, 2024 | 153.28M |
| April 01, 2024 | 155.80M |
| March 31, 2024 | 161.93M |
| March 28, 2024 | 143.79M |
| March 27, 2024 | 144.15M |
| March 26, 2024 | 139.83M |
| March 25, 2024 | 138.02M |
| March 22, 2024 | 149.20M |
| March 21, 2024 | 156.77M |
| March 20, 2024 | 163.98M |
| March 19, 2024 | 156.41M |
| March 18, 2024 | 160.74M |
| March 15, 2024 | 173.00M |
| March 14, 2024 | 153.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-19.25M
Minimum
Jun 24 2019
341.11M
Maximum
May 12 2023
119.78M
Average
110.36M
Median
Enterprise Value Benchmarks
| Anika Therapeutics Inc | 313.20M |
| Spero Therapeutics Inc | -1.021M |
| electroCore Inc | 33.09M |
| NovaBay Pharmaceuticals Inc | 5.64M |
| Palatin Technologies Inc | 22.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.11M |
| Revenue (Quarterly) | 6.102M |
| Total Expenses (Quarterly) | 21.96M |
| EPS Diluted (Quarterly) | -0.36 |
| Gross Profit Margin (Quarterly) | 70.75% |
| Profit Margin (Quarterly) | -231.2% |
| Earnings Yield | -41.81% |
| Normalized Earnings Yield | -41.81 |